Prevent Pneumococcal Disease in Infants and Young Children in the World's Poorest Countries
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) has entered into a second supply agreement which will broaden and extend the duration of the Company's commitment to help protect millions of infants and young children in the developing world from pneumococcal disease - the leading cause of vaccine-preventable death in young children.
Simcere and Bristol-Myers Squibb Enter Innovative Partnership
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company in China, have expanded the strategic partnership formed last year to include a second collaboration in a different therapeutic area.
Deeper levels of response with Tasigna® compared to Glivec®
- Details
- Category: Novartis
Phase III clinical trial data contribute to the growing evidence that adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase who are treated with Tasigna® (nilotinib) have deeper levels of response compared to those treated with Glivec® (imatinib)*[1],[2].
Merck Helps Eliminate Schistosomiasis in Africa
- Details
- Category: Merck Group
Merck KGaA announced its intention to further boost its efforts in the fight against the tropical disease schistosomiasis and to continue until the disease has been officially eliminated in Africa. The company plans to double its annual donation of tablets containing the active ingredient praziquantel from 25 million to 50 million in the medium term.
Abbott and Reata Pharmaceuticals Announce Agreement
- Details
- Category: Abbott
Abbott and Reata Pharmaceuticals have entered into a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators (AIMs).
Pfizer Elects CEO Ian Read as Chairman of the Board
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced that its Board of Directors has elected current President and Chief Executive Officer, Ian Read, as Chairman of the Board and Chief Executive Officer, effective immediately.
Most couples prefer spontaneity in the bedroom
- Details
- Category: Eli Lilly and Company
Sex is spontaneous, or unplanned, for the majority of men and women in the U.S. and around the world, a recent survey found. In the U.S., 76 percent of all respondents said they do not plan ahead for sex, compared to the global average of 86 percent.
More Pharma News ...
- Afinitor® significantly extends time women with advanced breast cancer live without tumor growth
- AstraZeneca to acquire generics company to broaden patient access to medicines in China
- AstraZeneca to streamline US sales organisation
- Prescribing Physicians, Patients and Institutions no Longer Required to Enroll in Nplate® NEXUS Program
- Pfizer Completes Acquisition of Excaliard
- Bristol-Myers Squibb Enters Clinical Collaboration Agreement with Tibotec Pharmaceuticals
- Novartis Foundation symposium looks at impact of Information and Communication Technology